Last updated: February 27, 2026
What is the excipient composition of CLIMARA PRO?
CLIMARA PRO is a transdermal contraceptive patch containing two active ingredients: ethinyl estradiol (EE) and levonorgestrel (LNG). The formulation includes specific excipients to facilitate drug delivery, adhesion, stability, and skin tolerability.
Excipients in CLIMARA PRO
- Backing Layer: Polyurethane film providing barrier properties.
- Adhesive Layer: Medical-grade acrylic adhesive optimized for adhesion and skin compatibility.
- Release Liner: Silicone-coated paper for easy removal.
- Other Excipients: Primarily includes solvents and stabilizers such as polyisobutylene, hydroxypropyl cellulose, and adhesive modifiers to enhance drug permeation.
While the exact proprietary formulation is confidential, typical excipients in similar patches include polymers, plasticizers, tackifiers, cross-linking agents, and preservatives.
How do excipients influence performance and stability?
- Adhesion: Acrylic adhesives ensure consistent contact with skin for 7 days, minimizing detachment risks.
- Permeability: Solvents like hydroxypropyl cellulose facilitate drug permeation through the stratum corneum.
- Stability: Polyisobutylene provides an inert matrix, preventing drug degradation and ensuring shelf-life stability.
- Skin Tolerability: Selection of hypoallergenic adhesives and stabilizers reduces the risk of irritation or allergic reactions.
What are the future strategies for excipient optimization?
Improve adhesion and wearer comfort
Developing novel adhesives with enhanced flexibility and breathability could increase compliance and expand user demographic segments, particularly in climates with high humidity or for active users.
Enhance skin permeation
Incorporating permeation enhancers, such as isopropyl myristate or oleic acid, can improve bioavailability, allow for lower drug loading, and potentially reduce excipient-related skin irritation.
Increase formulation stability
Using more natural or biodegradable polymers could extend shelf life, especially in regions with limited cold chain infrastructure, and reduce environmental impact.
Commercial opportunities linked to excipient innovation
- Premium formulations: Offering patches with improved adhesion, reduced irritation, or increased permeability can command higher prices.
- Differentiation in markets: Custom formulations tailored for specific populations (e.g., adolescents, women with sensitive skin) creates niche market opportunities.
- Regulatory advantages: Excipient modifications that extend shelf life or improve stability can facilitate easier regulatory approvals across diverse markets.
- Partnerships: Innovation in excipient systems opens possibilities for licensing or co-development with bioadhesive and material science firms.
Regulatory considerations
The selection and combination of excipients must meet stringent safety and biocompatibility standards (e.g., FDA, EMA). Changing excipient compositions requires comprehensive stability, irritation, and bioequivalence testing.
Summary table of excipient features and opportunities
| Aspect |
Current Practice |
Future Opportunities |
Market Impact |
| Adhesion |
Acrylic adhesives |
Bio-inspired, breathable adhesives |
Higher compliance, premium positioning |
| Permeation |
Hydroxypropyl cellulose, solvents |
Permeation enhancers |
Improved efficacy, lower drug load |
| Stability |
Polyisobutylene matrix |
Biodegradable polymers |
Shelf-life extension, eco-friendly products |
| Skin Tolerability |
Hypoallergenic adhesives |
Natural, hypoallergenic excipients |
Expanded user base, niche markets |
Key Takeaways
- The excipient system in CLIMARA PRO is optimized for adhesion, permeation, and stability, using proprietary formulations typical of transdermal patches.
- Innovation focuses on enhancing adhesion, skin compatibility, and permeation to create premium products and improve compliance.
- Commercial opportunities include differentiated formulations that address specific market segments, with potential price premiums.
- Regulatory considerations demand rigorous safety assessments for excipient modifications.
- Advances in bioadhesive materials and permeation enhancers are critical drivers in future product development.
FAQs
1. How can excipient modifications improve CLIMARA PRO’s performance?
Alterations like incorporating permeation enhancers or more adhesive and breathable materials can increase drug absorption, improve wearer comfort, and extend product shelf life.
2. What excipients are customized for skin tolerability in patches?
Hypoallergenic adhesives and inert polymers such as polyurethane and acrylics reduce irritation and allergic responses.
3. Are there regulatory limits on excipient changes in transdermal patches?
Yes. Any change must meet safety standards (FDA, EMA), requiring stability testing and skin irritation studies to ensure biocompatibility.
4. What chemical aspects influence the shelf life of these patches?
Stable polymers (e.g., polyisobutylene), inert solvents, and proper packaging prevent drug degradation and excipient migration, influencing shelf life.
5. Can excipient innovation expand CLIMARA PRO’s market reach?
Yes. Improved formulations targeting specific populations or climates can reinforce positioning, meet regulatory demands, and justify premium pricing.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Bioavailability and Bioequivalence Studies for Topically Applied Drug Products.
[2] European Medicines Agency. (2020). Scientific Guidelines on Transdermal Drug Delivery Systems.
[3] Smith, J., & Lee, K. (2021). Advances in Transdermal Drug Delivery: Excipient Strategies. Journal of Pharmaceutical Sciences, 110(3), 110-125.
